Virometix to kick off in-human studies of its vaccine against virus infections


The Belgian health authority, FAMHP, has approved Virometrix’s clinical trial application for the first-in-human phase 1 study of its respiratory syncytial virus (RSV) vaccine candidate, V-306. The startup secured funds to initiate the project.



Virometix is a Schlieren based biotech startup developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases. The company developed the “Synthetic Virus-Like Particle” (SVLP) platform technology as a new benchmark for designing high added value vaccines with superior properties in terms of safety, efficacy and stability.

Based on its technology, Virometix is developing a portfolio of preclinical candidates for the first-in-class vaccine for Respiratory Syncytial Virus (RSV), a seasonal virus-infection and the most common cause of serious acute lower respiratory disease. Infants and young children, as well as the elderly and immunocompromised, are, particularly, at risk. There is no approved for the prevention of RSV infection. According to Global Data, the market opportunity for RSV is estimated to reach $5.4 billion by 2028.

Following the approval of the Belgian health authority, FAMHP to conduct clinical trials, Virometrix will kick off phase 1 studies for its RSV vaccine candidate, V-306. The primary objective of the study will be to establish the safety profile of V-306 and secondary objectives will include an evaluation of the immunogenicity of V-306. Subjects will be followed for one year after the initial dose of V-306. The company has also revealed that it secured funding to initiate the trial in the coming weeks.

Anna Sumeray, Chief Executive Officer of Virometix, commented: “We are excited to be entering the clinic with V-306. Considerable efforts over the last few years to develop this innovative synthetic virus-like particle (SVLP) platform have resulted in a vaccine candidate that has the potential to protect vulnerable patients from the serious morbidity and mortality associated with RSV infection. We are looking forward to generating the first clinical data over the next few months.”